4510 related articles for article (PubMed ID: 3436737)
1. Development of host immunity to phenotypically diverse B16 melanoma clones. Implications for tumor growth and metastasis.
Stackpole CW; Alterman AL; Braverman S; Rappaport I
Invasion Metastasis; 1987; 7(6):346-66. PubMed ID: 3436737
[TBL] [Abstract][Full Text] [Related]
2. The role of intratumor environment in determining spontaneous metastatic activity of a B16 melanoma clone.
Alterman AL; Fornabaio DM; Kim YS; Stackpole CW
Invasion Metastasis; 1989; 9(4):242-53. PubMed ID: 2737843
[TBL] [Abstract][Full Text] [Related]
3. Growth characteristics of clonal cell populations constituting a B16 melanoma metastasis model system.
Stackpole CW; Alterman AL; Fornabaio DM
Invasion Metastasis; 1985; 5(3):125-43. PubMed ID: 3888909
[TBL] [Abstract][Full Text] [Related]
4. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
Stackpole CW; Demsey A
Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988
[TBL] [Abstract][Full Text] [Related]
5. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials.
LeGrue SJ; Hearn DR
Cancer Res; 1983 Nov; 43(11):5106-11. PubMed ID: 6616449
[TBL] [Abstract][Full Text] [Related]
6. Generation of phenotypic diversity in the B16 mouse melanoma relative to spontaneous metastasis.
Stackpole CW
Cancer Res; 1983 Jul; 43(7):3057-65. PubMed ID: 6850615
[TBL] [Abstract][Full Text] [Related]
7. Syngeneic monoclonal antibodies to B16 melanoma viral antigens.
Rappaport I; Alterman AL; Braverman S; Stackpole CW
Cancer Res; 1987 Oct; 47(20):5391-6. PubMed ID: 3652042
[TBL] [Abstract][Full Text] [Related]
8. Poorly metastatic tumor cell variants as primary targets of syngeneic antibody responses against murine melanoma.
Parratto NP; Odebralski JM; Kimura AK
Cancer Res; 1989 Jul; 49(14):3722-8. PubMed ID: 2736512
[TBL] [Abstract][Full Text] [Related]
9. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the metastatic properties of B16 melanoma clones isolated from cultured cell lines, subcutaneous tumors, and individual lung metastases.
Poste G; Doll J; Brown AE; Tzeng J; Zeidman I
Cancer Res; 1982 Jul; 42(7):2770-8. PubMed ID: 7083167
[TBL] [Abstract][Full Text] [Related]
11. Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice.
Falcioni R; Kennel SJ; Giacomini P; Zupi G; Sacchi A
Cancer Res; 1986 Nov; 46(11):5772-8. PubMed ID: 3756921
[TBL] [Abstract][Full Text] [Related]
12. High levels of Met-72 antigen expression: correlation with metastatic activity of B16 melanoma tumor cell variants.
Kimura AK; Xiang JH
J Natl Cancer Inst; 1986 Jun; 76(6):1247-54. PubMed ID: 3486997
[TBL] [Abstract][Full Text] [Related]
13. Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies.
Herd ZL
Cancer Res; 1987 May; 47(10):2696-703. PubMed ID: 3552203
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
15. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic diversity of murine B16 melanoma detected by anti-B16 monoclonal antibodies.
Johnson CW; Barth RF; Adams D; Holman B; Price JE; Sautins I
Cancer Res; 1987 Feb; 47(4):1111-7. PubMed ID: 2433032
[TBL] [Abstract][Full Text] [Related]
17. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
18. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity.
Seaman WE; Sleisenger M; Eriksson E; Koo GC
J Immunol; 1987 Jun; 138(12):4539-44. PubMed ID: 3584981
[TBL] [Abstract][Full Text] [Related]
19. Identification of immunogenic B16 melanoma-associated antigens.
Johnston D; Schachne JP; Bystryn JC
J Biol Response Mod; 1987 Apr; 6(2):108-20. PubMed ID: 3585408
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
